Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
- Resource Type
- Article
- Source
- Lancet Respiratory Medicine; Apr2024, Vol. 12 Issue 4, pe21-e30, 10p
- Subject
PULMONARY hypertension PHOSPHODIESTERASE inhibitors PULMONARY arterial hypertension THROMBOEMBOLISM HOSPITAL patients - Language
- ISSN
- 22132600